News about "Aurobindo Pharma"

Aurobindo Pharma Extends Timeline for Acquisition of Stake in Swarnaakshu Solar Power

Aurobindo Pharma has announced that the completion of its captive solar power purchase agreement and the acquisition of up to a 26 percent stake in Swarnaakshu Solar Power has been deferred to March 31, 2026, due to pending state government approvals for setting up the solar power plant.

Aurobindo Pharma | 30/12/2025 | By News Bureau

Aurobindo Pharma to Increase Stake in China JV for USD 5.12 Million

Aurobindo Pharma has announced plans to increase its shareholding in its China-based joint venture, Luoxin Aurovitas Pharma (Chengdu), by 20 percent through a cash investment of USD 5.12 million.

Aurobindo Pharma | 26/12/2025 | By Darshana |  101

Aurobindo Pharma's China Facility Running at Loss, Eyes Break-Even by Q4

The company’s CFO, S. Subramanian, indicated that while the plant is operating below margin, it is ramping up production and is on track to contribute positively to the company’s EBITDA in the near future.

Aurobindo Pharma | 24/11/2025 | By Darshana

Aurobindo's Subsidiary CuraTeQ Biologics Completes Phase 3 Clinical Study for Denosumab Biosimilar

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has successfully completed a pivotal clinical study of its denosumab biosimilar, evaluated against Amgen’s Prolia in 446 women with postmenopausal osteoporosis.

Aurobindo Pharma | 19/09/2025 | By Dineshwori |  284

Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions

This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.

Aurobindo Pharma | 18/09/2025 | By Dineshwori |  348

Aurobindo Pharma Expands Business in Malaysia with New Subsidiary

Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V.

Aurobindo Pharma | 18/09/2025 | By Dineshwori |  349

US FDA Completes Inspection at Aurobindo Pharma's Telangana Unit

The inspection of Aurobindo Pharma’s Apitoria Unit-I facility, conducted from 21-29 August, 2025, concluded with five observations.

Aurobindo Pharma | 30/08/2025 | By Dineshwori |  492

Aurobindo Pharma Wins UK MHRA Approval for Dazublys Trastuzumab Biosimilar

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers.

Aurobindo Pharma | 27/08/2025 | By Darshana |  203

CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys

CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.

Aurobindo Pharma | 26/08/2025 | By Dineshwori |  181

Aurobindo Pharma USA To Acquire Lannett For USD 250 Million, Enter ADHD Treatment Space

Aurobindo Pharma USA Inc., has entered into a definitive agreement to acquire 100 percent membership interest in Lannett Company LLC from its parent company, Lannett Seller Holdco, Inc.

Aurobindo Pharma | 31/07/2025 | By Dineshwori |  332